We are live on
!
Find out more
PHS
PFM Health Sciences Portfolio holdings
AUM
$1.1B
1-Year Est. Return
57.92%
This Fund
S&P 500
This Quarter
Est. Return
+18.38%
1 Year Est. Return
+57.92%
3 Year Est. Return
+183.93%
5 Year Est. Return
+283%
10 Year Est. Return
+2,507.28%
AUM
$3.71B
AUM Growth
-$281M
(-7%)
Cap. Flow
-$830M
Cap. Flow
% of AUM
-22.37%
Top 10 Holdings %
Top 10 Hldgs %
31.98%
Holding
127
New
29
Increased
29
Reduced
22
Closed
37
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
KITE
Kite Pharma, Inc.
KITE
|
+$73.3M |
| 2 |
McKesson
MCK
|
+$66.4M |
| 3 |
ServiceNow
NOW
|
+$60.6M |
| 4 |
DXC Technology
DXC
|
+$60M |
| 5 |
Microsoft
MSFT
|
+$58M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Jazz Pharmaceuticals
JAZZ
|
+$125M |
| 2 |
Marvell Technology
MRVL
|
+$118M |
| 3 |
Biogen
BIIB
|
+$102M |
| 4 |
WFT
Weatherford International plc
WFT
|
+$102M |
| 5 |
CSC
Computer Sciences
CSC
|
+$98M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 40.08% |
| 2 | Technology | 13.76% |
| 3 | Consumer Discretionary | 5.54% |
| 4 | Communication Services | 4.09% |
| 5 | Financials | 3.83% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
PUT
iShares Russell 2000 ETF
IWM
$80.9B
| $5.33M | 0.14% |
+37,800
| New | +$5.23M |
|
|
CSOD
77
DELISTED
Cornerstone OnDemand, Inc.
CSOD
| $3.74M | 0.1% |
104,588
-683,495
| -87% | -$25.6M |
|
|
JUNO
78
DELISTED
Juno Therapeutics, Inc.
JUNO
| $3.43M | 0.09% |
114,695
| – | – |
|
|
IVTY
79
DELISTED
Invuity, Inc
IVTY
| $3.27M | 0.09% |
451,761
+21,870
| +5% | +$170K |
|
80
Peabody Energy
BTU
$2.78B
| $2.98M | 0.08% |
+122,101
| New | +$3.02M |
|
|
81
Biogen
BIIB
$29.9B
| $1.1M | 0.03% |
4,046
-386,618
| -99% | -$102M |
|
82
CALL
Coherus Oncology
CHRS
$217M
| $895K | 0.02% |
+62,400
| New | +$1.2M |
|
83
AbbVie
ABBV
$458B
| – | – |
-526,354
| Closed | -$34.3M |
|
84
Ardelyx
ARDX
$1.24B
| – | – |
-1,109,574
| Closed | -$14M |
|
85
Collegium Pharmaceutical
COLL
$1.14B
| – | – |
-794,550
| Closed | -$7.99M |
|
|
VISN
86
Vistance Networks Inc
VISN
$2.66B
| – | – |
-1,142,225
| Closed | -$47.6M |
|
87
Cirrus Logic
CRUS
$6.74B
| – | – |
-183,100
| Closed | -$11.1M |
|
88
Hain Celestial
HAIN
$47.8M
| – | – |
-989,755
| Closed | -$36.8M |
|
89
Herbalife
HLF
$1.23B
| – | – |
-906,124
| Closed | -$26.3M |
|
|
HOLX
90
DELISTED
Hologic
HOLX
| – | – |
-1,213,261
| Closed | -$51.6M |
|
91
Inogen
INGN
$167M
| – | – |
-61,951
| Closed | -$4.8M |
|
|
92
CALL
Jazz Pharmaceuticals
JAZZ
$15.9B
| – | – |
-192,900
| Closed | -$28M |
|
|
93
Jazz Pharmaceuticals
JAZZ
$15.9B
| – | – |
-864,276
| Closed | -$125M |
|
94
Eli Lilly
LLY
$1.07T
| – | – |
-575,249
| Closed | -$48.4M |
|
95
ArcelorMittal
MT
$50.4B
| – | – |
-183,797
| Closed | -$4.6M |
|
96
CALL
iShares S&P 100 ETF
OEF
$19.8B
| – | – |
-137,400
| Closed | -$40.3M |
|
|
97
PUT
iShares S&P 100 ETF
OEF
$19.8B
| – | – |
-421,900
| Closed | -$124M |
|
|
SAGE
98
DELISTED
Sage Therapeutics
SAGE
| – | – |
-75,158
| Closed | -$5.34M |
|
99
Starbucks
SBUX
$118B
| – | – |
-1,327,769
| Closed | -$77.5M |
|
|
SCHW
100
Charles Schwab
SCHW
$177B
| – | – |
-1,033,855
| Closed | -$42.2M |
|
Similar funds
DAM
MAM
LCM
PRS
DAM
KCM
CF
MIA
PFM Health Sciences's Q2 2017 Portfolio in Review
As of Q2 2017, PFM Health Sciences held 127 positions worth $3.71B, down 7% from $3.99B the previous quarter. Its ten largest holdings account for 32% of the portfolio.
PFM Health Sciences withdrew a net $830M in Q2 2017, closing 37 positions and reducing 22 holdings. Its most notable exit was Jazz Pharmaceuticals, an estimated $125M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 40% of assets, up from 39% a quarter earlier, followed by Technology and Consumer Discretionary.
Against the trend, PFM Health Sciences opened a new position in McKesson worth $72.1M.
- PFM Health Sciences's largest Q2 2017 buy was McKesson: 438,055 shares worth $72.1M.
- PFM Health Sciences added most to Kite Pharma, Inc. in Q2 2017, an estimated $73.3M increase.
- PFM Health Sciences's biggest Q2 2017 reduction was Marvell Technology, cutting an estimated $118M.
- PFM Health Sciences fully exited Jazz Pharmaceuticals in Q2 2017, selling an estimated $125M.
- PFM Health Sciences's ten largest holdings make up 32% of its $3.71B portfolio in Q2 2017.
- PFM Health Sciences opened 29 new positions and closed 37 in Q2 2017.
- PFM Health Sciences's portfolio value fell 7% quarter-over-quarter to $3.71B.
Based on PFM Health Sciences's 13F filing for Q2 2017, filed 14 Aug 2017.